Detalles de la búsqueda
1.
Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence.
Int J Technol Assess Health Care
; 30(4): 345-53, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25399914
2.
Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
J Med Econ
; 21(2): 113-121, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28880737
3.
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Clin Drug Investig
; 38(4): 319-331, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29247383
4.
Performance Goals for an Adjunct Diagnostic Test to Reduce Unnecessary Biopsies After Screening Mammography: Analysis of Costs, Benefits, and Consequences.
J Am Coll Radiol
; 13(11S): R81-R88, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27814820
5.
Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer.
Clinicoecon Outcomes Res
; 6: 37-47, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24470765
6.
Performance goals for an adjunct diagnostic test to reduce unnecessary biopsies after screening mammography: analysis of costs, benefits, and consequences.
J Am Coll Radiol
; 10(12): 924-30, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24295942
Resultados
1 -
6
de 6
1
Próxima >
>>